Mark G. Kris, MD
Chief, Thoracic Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan-Kettering Cancer Center
Weill Medical College of Cornell University
New York, New York

Mark G. Kris, MD is chief of the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center and attending physician at Memorial Hospital for Cancer and Allied Diseases, New York, New York. He is professor of medicine at the Weill Medical College of Cornell University and serves as co-leader of Memorial Sloan-Kettering’s Multidisciplinary Thoracic Disease Management Team. He is the first incumbent of the William and Joy Ruane Chair in Thoracic Oncology.

After receiving his medical degree from the Weill Medical College of Cornell University, he served as chief medical resident and fellow in medical oncology at Memorial Sloan-Kettering Cancer Center. He is certified in internal medicine and medical oncology.

He has authored or coauthored 190 original scientific publications. Dr Kris holds memberships in the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. He heads the Antiemetic Guideline Panel for the 2006 update for the American Society of Clinical Oncology. He is a member of the guideline panels on antiemetics and non-small cell lung cancer for the National Comprehensive Cancer Center Network. He serves as co-chair of the American Society of Clinical Oncology guideline panel for adjuvant chemotherapy and radiation for non-small cell lung cancer. In addition, he is a fellow of the American College of Physicians and the American College of Chest Physicians. Dr Kris serves on the Medical Advisory Board of Cancer Care, Inc. and The Joan’s Legacy Foundation.

Dr Kris is a specialist in thoracic malignancies (including lung cancer, thymoma, and neuroendocrine tumors arising in the chest). He is a clinical and translational investigator. His research includes: the evaluation of new anticancer agents, the development of treatments targeting lung cancer, multimodality therapy, the testing of antiemetics, and identifying better ways to manage the physical symptoms caused by cancer. He is particularly interested in developing strategies to select treatments for patients based on clinical factors and molecular characteristics of their tumor specimens.